Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **October 31, 2006**

Biogen Idec Inc.

(Exact name of registrant as specified in its charter)

Delaware	**0-19311**	**33-0112644**
(State or other jurisdiction of incorporation)	(Commission file number)	(IRS Employer Identification No.)

14 Cambridge Center, Cambridge, Massachusetts	**02142**
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code (**617) 679-2000**

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Table of Contents

Item 2.02 Results of Operations and Financial Condition.

On October 31, 2006, the registrant issued a press release announcing its unaudited results of operations and financial condition for the three months ended September 30, 2006. A copy of the press release is furnished as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure.

On October 31, 2006, the registrant posted presentation slides on its corporate website in connection with an earnings conference and webcast. A copy of the presentation is furnished as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits.

The press release and presentation slides are being furnished pursuant to Item 2.02 and Item 7.01 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

99.1 Registrant's press release dated October 31, 2006.
99.2 Registrant's presentation dated October 31, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biogen Idec Inc.

By: /s/ Daniel S. Char
Daniel S. Char
Associate General Counsel and
Assistant Secretary

Date: October 31, 2006

Table of Contents

EXHIBIT INDEX

Exhibit Number	Description
99.1	Registrant's press release dated October 31, 2006.
99.2	Registrant's presentation dated October 31, 2006.

Exhibit 99.1



Media Contact:
Jose Juves
Director, Public Affairs
Biogen Idec
Tel: (617) 914-6524

Investment Community Contact:
Elizabeth Woo
Vice President, Investor Relations
Biogen Idec
Tel: (617) 679-2812

FOR IMMEDIATE RELEASE

Biogen Idec Reports Third Quarter 2006 Results

Cambridge, MA, October 31, 2006 — Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology company with leading products and capabilities in oncology, neurology and immunology, today reported its third quarter 2006 results.

Third Quarter 2006 Highlights

- Total revenues for the third quarter were $703 million vs. prior year of $596 million, an increase of 18%, driven primarily by AVONEXÒ (Interferon beta-1a) worldwide sales up 19% to $445 million and RITUXANÒ (rituximab) revenues from the unconsolidated joint business arrangement up 12% to $204 million.
- On a reported basis, calculated in accordance with U.S. generally accepted accounting principles (GAAP), the diluted earnings per share was $0.45 for the third quarter. The GAAP earnings reflect amortization of acquired intangible assets and the impact of share-based payment expense in accordance with FAS 123R, including employee stock options.
- Biogen Idec's third quarter 2006 non-GAAP diluted earnings per share (EPS) was $0.60, up 67% from the same period last year.
- TYSABRIÒ (natalizumab) has been launched in the U.S. and Europe for the treatment of relapsing forms of multiple sclerosis (MS) following regulatory approvals in June. To date, over 2,200 patients are being treated with TYSABRI in the U.S. and Europe. Global in-market net sales of TYSABRI in the third quarter of 2006 were $8 million, comprised of $5 million in the U.S. and $3 million in Europe.
- Biogen Idec signed three collaboration and licensing agreements during the third quarter of 2006: Aviptadil with mondoBIOTECH, RNAi therapy with Alnylam, and CDP323 with UCB.

MORE

James Mullen, Biogen Idec's Chief Executive Officer, commented, "Robust double-digit growth, driven by strong AVONEX and RITUXAN performance, continues to define our business. Returning TYSABRI to the MS community was a remarkable achievement, and we expect this will enhance our neurology franchise and begin to accelerate top-line growth over the coming quarters. In keeping with our strategic plan, we made key investments in our pipeline this quarter, including three collaboration agreements, building on the momentum of last quarter's two acquisitions."

Financial Performance

On a reported basis, calculated in accordance with GAAP, Biogen Idec reported earnings per diluted share of $0.45 for the third quarter of 2006 (Q3 2005 diluted EPS was $0.08). Net income was $157 million in the third quarter of 2006 (Q3 2005 net income was $27 million).

On a non-GAAP basis, Biogen Idec reported non-GAAP EPS of $0.60 for the third quarter of 2006 (Q3 2005 non-GAAP diluted EPS was $0.36). Non-GAAP net income was $207 million in the third quarter of 2006 (Q3 2005 non-GAAP net income was $122 million).

The differences between non-GAAP net income and EPS, and GAAP net income and EPS in the third quarter are itemized in Table 3, and are primarily due to:

- Pre-tax charges related to the Biogen and Idec merger and the acquisitions of Conforma and Fumapharm, including $60 million in amortization of acquired intangible assets and $3 million in fair value step-up of acquired inventory.
- Pre-tax share-based payment expense under FAS 123R of $13 million (or $0.03 per share), primarily employee stock option expense.

Revenue Performance for the Three Months ended September 30, 2006

- Revenues from AVONEX increased 19% to $445 million (Q3 2005: $375 million).
  - U.S. sales increased 14% to $268 million (Q3 2005: $235 million).
  - International sales increased 26% to $177 million (Q3 2005: $140 million).
- Revenues from Biogen Idec's joint business arrangement with Genentech, Inc. related to RITUXAN were up 12% to $204 million (Q3 2005: $182 million). All U.S. sales of RITUXAN are recognized by Genentech and Biogen Idec records its share of the pretax co-promotion profits on a quarterly basis.
  - U.S. net sales of RITUXAN increased 12% to $509 million in the third quarter of 2006 (Q3 2005: $456 million), as reported by Genentech.
- During the third quarter, Biogen Idec recognized revenue of $19 million related to TYSABRI.
  - $5 million related to product sold in this quarter.
  - $14 million related to sales of TYSABRI to Elan in 2005. This represents product sold to Elan, but not yet shipped by them at the time of withdrawal. The amount was deferred until the uncertainty about the ultimate disposition of the product was eliminated in Q3 2006.

- Revenues from other products were $11 million (Q3 2005: $17 million). Current revenues include FUMADERMÒ (fumaric acid esters) in Germany from the Fumapharm acquisition. Prior year revenues included AMEVIVEÒ(alefacept), which has since been divested. Details are provided in Table 4.
- Royalties were $22 million (Q3 2005: $23 million).

Share Repurchase Program

In October, Biogen Idec's Board of Directors authorized the repurchase of up to 20 million shares of its common stock. The repurchased stock will provide the Company with authorized shares for general corporate purposes, such as stock to be issued under employee stock option and stock purchase plans. The share buyback will largely be funded through operating cash flow and is expected to be accretive to EPS.

The Company had approximately 336 million shares of common stock outstanding at the end of Q3 2006.

Financial Guidance

Biogen Idec is raising full year 2006 non-GAAP earnings per share guidance to exceed $2.20. This assumes ongoing business development activity for the remainder of the year at a similar level to third quarter 2006.

Guidance for full year 2006 reported earnings per share (GAAP-based financial measure) is estimated to exceed $0.65, excluding any future acquisitions or other transactions. The Company cannot predict with certainty the nature or the amount of non-operating or unusual charges for the fourth quarter. The Company does anticipate in its full year estimate that certain charges related to purchase accounting for completed transactions will be included in the GAAP financials, such as the write-off of acquired in-process R&D ($331 million), amortization of intangibles (approximately $270 million, gain on settlement of existing collaboration agreement ($34 million), and inventory step up (approximately $8 million). In addition, the impact of stock options being expensed due to FAS 123R in 2006 is estimated to be in the range of $50-60 million, or approximately $0.10 — $0.12 per diluted share. Additionally, the Company anticipates that it may have to take other charges in the fourth quarter and that such charges, if material, would cause reported earnings per share to further differ from non-GAAP earnings per share.

The Company now anticipates that 2006 capital expenditures will be in the range of $190 — $220 million.

Recent Highlights

- On September 14th, Biogen Idec and mondoBIOTECH announced the signing of an exclusive collaboration and license agreement for Biogen Idec to develop, manufacture and commercialize Aviptadil, a clinical compound for the treatment of pulmonary arterial hypertension.

- On September 20th, Biogen Idec and Alnylam Pharmaceuticals announced a collaboration to discover and develop RNAi therapeutics for the potential treatment of progressive multifocal leukoencephalopathy.
- On September 28th and 29th, Biogen Idec and Elan announced new data presented at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis Congress. Long-term follow-up data from TYSABRI clinical trial patients showed TYSABRI has a sustained effect on relapse rate in MS patients treated for up to three years. Long-term follow-up data from the Phase III AFFIRM monotherapy study demonstrated that treatment with TYSABRI significantly reduced the proportion of MS patients with worsening cognitive function as measured by the 3-second Paced Auditory Serial Addition Test (PASAT 3).
- On September 29th, Biogen Idec and Genentech announced that the U.S. Food and Drug Administration approved, after a Priority Review, two additional uses for RITUXAN for patients with CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). One new indication for RITUXAN is for first-line treatment of previously-untreated patients with follicular NHL in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy. The second new indication is for the treatment of low-grade NHL in patients with stable disease or who achieve a partial or complete response following first-line treatment with CVP chemotherapy.
- On October 2nd, Biogen Idec and UCB announced a global collaboration, effective in the third quarter 2006, to jointly develop and commercialize CDP323 for the treatment of relapsing-remitting MS and other potential indications CDP323 is an orally active small molecule a 4-integrin inhibitor expected to enter Phase II clinical trials next year.
- On October 6th, Biogen Idec and Elan Corporation announced that data presented at the Academy of Managed Care Pharmacy's 2006 Educational Conference show that in Phase III studies TYSABRI therapy significantly reduced corticosteroid use and hospitalizations, and increased the proportion of MS patients with no disease activity. Findings were also presented that demonstrated the positive impact of TYSABRI on a number of health-related quality of life of measures and the cost-effectiveness of MS therapies.
- On October 24th, Biogen Idec and Elan announced that data show TYSABRI maintained remission in Crohn's disease patients treated for longer than two years. These data, presented at the 14th United European Gastroenterology Week and at the Annual American College of Gastroenterology, were part of an open label extension study of patients who participated in the ENACT-2 trial.

Use of Non-GAAP Financial Measures

The non-GAAP financial measures presented in this press release are utilized by Biogen Idec management to gain an understanding of the comparative financial performance of the Company. Management believes that the non-GAAP financial measures are useful because they exclude those non-operational activities or transactions that are not necessarily relevant to understanding the trends of the Company or the prospects of

future performance such as charges related to in-process R&D, amortization of intangibles, inventory step-up values, and employee stock option expense. Management uses these measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in the Company's business over time. The presentation of this information is not meant to be considered in isolation or as a substitute for GAAP financial measures.

Conference Call and Webcast

The Company's earnings conference call for the third quarter will be broadcast via the Internet at 8:30 a.m. ET on October 31, 2006, and will be accessible through the investor relations section of Biogen Idec's homepage, http://www.biogenidec.com.

About Biogen Idec

Biogen Idec (NASDAQ: BIIB) creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com.

Safe Harbor

This press release contains forward-looking statements regarding expected future financial results, including revenue growth rates, EPS, capital expenditures, the potential for TYSABRI in MS, and the Company's share repurchase program.

A number of risks and uncertainties could cause actual results to differ materially. For example, financial results and external growth opportunities may be affected by a number of factors, including any unexpected slowness in the demand for TYSABRI, AVONEX, and RITUXAN, the impact of reimbursement and pricing decisions related to the Company's products, the impact of competitive products on the Company's products, any material decreases in royalties which the Company receives, the impact of litigation, increases in costs related to or an inability for us to enter into in-licensing deals, collaborations or acquisitions on acceptable terms, increases in costs related to research and development of new products as well as increases in costs related to development of existing products in new indications, and any material issues, delays or failures related to the manufacturing or supply of the Company's products.

The potential for TYSABRI is subject to a number of risks and uncertainties. Factors which could cause actual results to differ materially from the Company's current expectations include the risk that the incidence and/or risk of PML or other opportunistic infections in patients treated with TYSABRI may be higher than observed in clinical trials, that TYSABRI may not be accepted by the medical community and patients, or that the Company may encounter other unexpected issues.

Our long-term growth will depend on the successful development and commercialization of new products, such as CDP323 and Aviptadil, as well as the development and commercialization of existing products in new indications. Drug development involves a high degree of risk. For example, the plans for our development programs could be

negatively affected if unexpected concerns arise from additional data or analysis, if regulatory authorities require additional information or further studies, or if we were to encounter other unexpected hurdles.

For more detailed information on the risks and uncertainties associated with these forward looking statements and the Company's other activities, see "Risk Factors" in the Company's quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2006 and the other periodic and current reports filed by the Company with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

TABLE 1
Biogen Idec Inc.
September 30, 2006
Consolidated Statements of Income
(in thousands, except per share amounts)
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2006	2005	2006	2005
REVENUES				
Product	$ 475,096	$ 391,366	$ 1,317,696	$ 1,187,773
Unconsolidated joint business	203,820	181,597	593,296	526,984
Royalties	21,867	23,117	60,714	71,600
Corporate partner	2,709	131	3,002	3,290
Total revenues	703,492	596,211	1,974,708	1,789,647
COST AND EXPENSES				
Cost of goods sold and royalty revenues	66,792	89,561	212,280	260,262
Research and development	211,033	227,039	518,910	579,357
Selling, general and administrative	168,153	161,410	492,833	475,637
Amortization of acquired intangible assets	60,011	75,990	206,978	228,746
Acquired in-process R&D	—	—	330,520	—
Impairment and loss on sale of long lived assets	175	21,046	(923)	102,904
Gain on settlement of license agreement	—	—	(34,192)	—
Total cost and expenses	506,164	575,046	1,726,406	1,646,906
Income from operations	197,328	21,165	248,302	142,741
Other income, net	22,319	11,192	62,790	8,318
INCOME BEFORE TAXES AND CUMULATIVE EFFECT OF ACCOUNTING CHANGE	219,647	32,357	311,092	151,059
Income taxes	63,048	5,172	205,916	45,910
INCOME BEFORE CUMULATIVE EFFECT OF ACCOUNTING CHANGE	156,599	27,185	105,176	105,149
Cumulative effect of accounting change, net of income tax	—	—	3,779	—
NET INCOME	$ 156,599	$ 27,185	$ 108,955	$ 105,149
BASIC EARNINGS PER SHARE				
Income before cumulative effect of accounting change	$ 0.46	$ 0.08	$ 0.31	$ 0.31
Cumulative effect of accounting change, net of income tax	—	—	0.01	—
BASIC EARNINGS PER SHARE	$ 0.46	$ 0.08	$ 0.32	$ 0.31
DILUTED EARNINGS PER SHARE				
Income before cumulative effect of accounting change	$ 0.45	$ 0.08	$ 0.30	$ 0.31
Cumulative effect of accounting change, net of income tax	—	—	0.01	—
DILUTED EARNINGS PER SHARE	$ 0.45	$ 0.08	$ 0.31	$ 0.31
SHARES USED IN CALCULATING:				
BASIC EARNINGS PER SHARE	338,021	336,536	339,527	334,819
DILUTED EARNINGS PER SHARE	344,754	340,859	345,999	346,581

Numbers may not foot due to rounding.

TABLE 2
Biogen Idec Inc.
September 30, 2006
Condensed Consolidated Balance Sheets
(in thousands)

	September 30, 2006 (Unaudited)	December 31, 2005
ASSETS		
Cash, cash equivalents and securities available-for-sale	$ 661,019	$ 850,753
Accounts receivable, net	282,519	265,742
Inventory	155,119	182,815
Other current assets	286,500	318,771
Total current assets	1,385,157	1,618,081
Long-term securities available-for-sale	1,372,772	1,204,378
Property and equipment, net	1,246,116	1,174,396
Intangible assets, net	2,795,620	2,975,601
Goodwill	1,153,980	1,130,430
Other	232,913	264,061
TOTAL ASSETS	$ 8,186,558	$ 8,366,947
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities	$ 495,010	$ 583,036
Long-term deferred tax liability	653,433	762,282
Non-current liabilities	143,241	115,753
Shareholders' equity	6,894,874	6,905,876
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 8,186,558	$ 8,366,947

Numbers may not foot due to rounding.

TABLE 3
Biogen Idec Inc.
September 30, 2006
Condensed Consolidated Statements of Income — Non-GAAP
(in millions, except per share amounts)
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
EARNINGS PER SHARE	**2006**	**2005**	**2006**	**2005**
GAAP earnings per share — Diluted	$ 0.45	$ 0.08	$ 0.31	$ 0.31
Adjustment to net income (as detailed below)	0.15	0.28	1.40	0.78
Non-GAAP earnings per share — Diluted	$ 0.60	$ 0.36	$ 1.71	$ 1.09
SHARES USED IN CALCULATING DILUTED EARNINGS PER SHARE	345	341	346	347
An itemized reconciliation between net income on a GAAP basis and net income on a non-GAAP basis is as follows:				
GAAP net income	$ 156.6	$ 27.2	$ 109.0	$ 105.1
Adjustments:				
COGS: Fair value step up of inventory acquired from former Biogen, Inc. and Fumapharm AG	2.9	11.3	7.8	29.6
COGS: Stock option expense	—	—	0.1	—
R&D: Costs associated with sale of Oceanside Manufacturing Facility	—	—	—	1.9
R&D: Merger related and purchase accounting costs	—	0.2	—	0.2
R&D: Severance and restructuring	—	19.6	0.3	19.6
R&D: Stock option expense	5.2	—	16.4	—
SG&A: Merger related and purchase accounting costs	—	0.3	0.1	0.8
SG&A: Severance and restructuring	—	7.6	1.6	7.6
SG&A: Stock option expense	7.7	—	24.3	—
Purchase accounting: Amortization of acquired intangible assets related to the merger with former Biogen, Inc., Conforma Therapeutics Corporation and Fumapharm AG	60.0	76.0	207.0	228.7
Purchase accounting: In-process research and development related to the acquisition of Conforma Therapeutics Corporation and Fumapharm AG	—	—	330.5	—
Purchase accounting: Gain on settlement of license agreement with Fumapharm AG	—	—	(34.2)	—
Impairment and loss on sale of long lived assets	0.2	21.0	(0.9)	96.6
Income taxes: Income tax effect of reconciling items	(25.6)	(40.9)	(64.9)	(113.0)
Cumulative effect of accounting change from adoption of FAS123R, net of income tax	—	—	(3.8)	—
Non-GAAP net income	$ 207.0	$ 122.3	$ 593.3	$ 377.1

Numbers may not foot due to rounding.

The non-GAAP financial measures presented in this table are utilized by Biogen Idec management to gain an understanding of the comparative financial performance of the Company. Management believes that the non-GAAP financial measures are useful because they exclude those non-operational activities or transactions that are not necessarily relevant to understanding the trends of the Company or the prospects of future performance. Management uses these measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in the Company's business over time. The presentation of this information is not meant to be considered in isolation or as a substitute for GAAP financial measures.

TABLE 4
Biogen Idec Inc.
September 30, 2006
Product Revenues
(in thousands)
(Unaudited)

	Three Months Ended September 30,	
	2006	**2005**
PRODUCT REVENUES		
Avonex®	$ 445,156	$ 374,708
Amevive®	411	11,631
Tysabri®	18,654**	(196)
Zevalin®	4,438	5,223
Fumaderm®	6,437	—
Total product revenues	$ 475,096	$ 391,366

	Nine Months Ended September 30,	
	2006	**2005**
PRODUCT REVENUES		
Avonex®	$ 1,267,961	$ 1,130,082
Amevive®	11,148	36,104
Tysabri®	18,262**	4,853
Zevalin®	13,888	16,734
Fumaderm®	6,437	—
Total product revenues	$ 1,317,696	$ 1,187,773

** Biogen Idec's TYSABRI revenues in Q3 2006 includes $14 million of revenue that was originally deferred at the time of the initial TYSABRI launch in accordance with the Company's revenue recognition policy. The revenue was recognized in Q3 2006, as the ultimate disposition of the product was determined during the current period.

Numbers may not foot due to rounding.

Exhibit 99.2


biogen idec
Biogen Idec Q3 2006
Earnings Conference Call and Webcast
October 31, 2006
Fair Disclosure: Under "Reg FD," the SEC has set out a series of regulations regarding selective disclosure of material non-public information. In an effort to comply with these regulations, we believe it is important to state at the outset that our presentation today will not address, nor will we answer any questions relating to, material non-public information.
The information we plan to share with you today includes only information that is already in the public domain and/or information that is not material.

Safe Harbor Statement

- This presentation contains forward-looking statements regarding expected future financial results, product development, and the potential for TYSABRI in MS.
- A number of risks and uncertainties could cause actual results to differ materially. For example, financial results and external growth opportunities may be affected by a number of factors, including any unexpected slowness in the demand for TYSABRI, AVONEX, and RITUXAN, the impact of reimbursement and pricing decisions related to the Company's products, the impact of competitive products on the Company's products, any material decreases in royalties which the Company receives, the impact of litigation, increases in costs related to or an inability for us to enter into in-licensing deals, collaborations or acquisitions on acceptable terms, increases in costs related to research and development of new products as well as increases in costs related to development of existing products in new indications, and any material issues, delays or failures related to the manufacturing or supply of the Company's products.
- The potential for TYSABRI is subject to a number of risks and uncertainties. Factors which could cause actual results to differ materially from the Company's current expectations include the risk that the incidence and/or risk of PML or other opportunistic infections in patients treated with TYSABRI may be higher than observed in clinical trials, that TYSABRI may not be accepted by the medical community and patients, or that the Company may encounter other unexpected issues.
- Our long-term growth will depend on the successful development and commercialization of new products, such as BG-12, galiximab and lumiliximab, as well as the development and commercialization of existing products in new indications. Drug development involves a high degree of risk. For example, the plans for our development programs could be negatively affected if unexpected concerns arise from additional data or analysis, if regulatory authorities require additional information or further studies, or if we were to encounter other unexpected hurdles.
- For more detailed information on the risks and uncertainties associated with these forward looking statements and the Company's other activities, see "Risk Factors" in the Company's quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2006 and the other periodic and current reports filed by the Company with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Q3 2006 Earnings Call Agenda

- Introduction
  - Elizabeth Woo, VP Investor Relations

- Overview
  - Jim Mullen, CEO

- Tysabri Launch
  - Bob Hamm, SVP Neurology SBU

- Pipeline Update
  - Burt Adelman, EVP Portfolio Strategy

- Financial Performance
  - Peter Kellogg, CFO
- Q&A

biogen idec

James Mullen
Chief Executive Officer

Q3 2006 Overview

Q3 2006 Highlights

- **Successful Tysabri launch and initial rollout**
  - Over 2,200 patients being treated worldwide
- **Pipeline progress**
  - Aiming to provide continuum of care for MS patients
  - BG-12 for relapsing remitting MS, Galiximab for NHL & Lumiliximab for CLL
- **Solid financial performance**
  - Strong revenue and earnings growth
- **Continued progress on business development front**
  - Three agreements signed in Q3 2006
    - Aviptadil for PAH with mondoBIOTECH
    - RNAi for PML with Alnylam
    - CDP323 for MS with UCB
  - Adding to momentum from PDL BioPharma, Conforma & Fumapharm deals over last 15 months

biogen idec

biogen idec

Bob Hamm
SVP, Neurology Strategic Business Unit

Tysabri Launch

Tysabri Launch Progress

- **July 2006 launch in both the EU and US**
  - European CHMP approval announced June 29, 2006
  - US FDA approval announced on June 5, 2006
  - Steady progress towards our goals
- **Dosed over 2,200 individual patients with Tysabri worldwide to date**
  - In U.S.: ~4,500 TOUCH start forms, with ~1,700 of those patients infused
    - Approximately 750 prescribing physicians
    - Approximately ¾ of Tysabri patients switching from ABCR therapy
      - Switchers coming off therapies in line with market shares
    - Remaining ¼ of Tysabri patients include:
      - Quitters
      - Switching from other drugs (e.g. oral steroids)
      - A few "hot naïve" patients
  - In Europe: 500 to 600 patients infused to date, primarily in Germany
    - Majority of switchers coming off high dose β interferon

Tysabri US Launch

- **TOUCH Prescribing Program**
  - Goal of 2,000 to 2,500 practices/infusion centers trained by year end
    - Represents access for >50% of indicated RRMS patients
    - Rollout initially focused on
      - Large MS centers
      - Hospital based infusion sites associated with large neurology centers
    - Majority of physicians returning from 1st launch
  - On track with approximately 1,000 practices/infusion centers trained to date

- **Reimbursement**
  - Payors impressed with the AFFIRM data
  - TOUCH program mentioned as a positive by payor plans
    - Ensures appropriate patient selection & informed risk-benefit decision-making
    - Many payors adopting TOUCH as prior authorization process
  - While coverage has been favorable, working through normal consistency of coverage and reimbursement issues inherent in a new drug launch
  - On track against our expectations

Tysabri European Launch

- **EU RiskMAP vs. US plan**
  - Both contain educational tools for patients and physicians and studies to better understand the risk of PML
  - No mandatory registry required in EU
- **Country specific launches**
  - As of Q3: Germany, UK, Ireland, Denmark, Sweden, Netherlands, Austria, Finland, Norway
  - Planned for Q4 2006: Canada, Italy
  - Planned for H1 2007: Other major EU markets (e.g. France)
- **Reimbursement**
  - Established in Germany and Ireland
  - Other countries are working through the reimbursement process normally based on local country procedures
  - On track against our expectations

biogen idec

Burt Adelman, MD
EVP, Portfolio Strategy

Pipeline Update

Pipeline Highlights

- **Demonstrated expertise and execution**
  - Avonex remains leading MS therapy more than 10 years from launch
  - Global launch of Tysabri, including re-launch in US, a major achievement
  - Progress on clinical pipeline
- **Ongoing development of pipeline**
  - BG-12 in relapsing remitting MS
  - Anti-CD80 (galiximab) in NHL
  - Anti-CD23 (lumiliximab) in CLL
- **Aiming to provide continuum of care for multiple sclerosis patients**
- **Expanding expertise in Oncology, Immunology and other therapeutic areas**

biogen idec

Multiple Sclerosis Portfolio Strategy

- Working assumption that a single drug will not work for every patient throughout the course of the disease
  - Efficacy, safety, side effects and convenience all play a role
  - Entire profile of drug balanced against the progression of the disease
  - Patients will likely cycle through several therapies
- Broad MS franchise should provide multiple options for patients and positions Biogen Idec to remain the leading MS company in this rapidly evolving field

Multiple Sclerosis Pipeline



biogen idec

Immunology Pipeline



Oncology Pipeline

biogen idec

biogen idec

Peter Kellogg
Chief Financial Officer

Financial Performance

Total Revenue Q3 2006

- Total revenues $703 million for Q3 2006, up 18% year-over-year
- Driven by growth in core franchises Avonex and Rituxan



biogen idec

Avonex Worldwide Sales Q3 2006

- Avonex sales $445 million for Q3 2006, up 19% year-over-year
- Strong ex-US growth a major driver



biogen idec

Rituxan Sales and Profit Share Q3 2006

- US sales of Rituxan recognized by partner Genentech
- Rituxan US sales $509 million for Q3 2006, up 12% year-over-year
- Revenue from unconsolidated joint business to Biogen Idec of $204 million for Q3 2006, up 12% year-over-year





biogen idec

Tysabri Revenues

- **Tysabri sales**
  - Total end user or in-market revenues $8.1 million
    - $5.4 million of US end user sales
    - $2.7 million of European end user sales, primarily from Germany
- **Tysabri revenue**
  - Biogen Idec's Tysabri revenue was $19 million in Q3 2006
    - $5 million related to product sold in this quarter
    - $14 million related to sales of TYSABRI to Elan in 2005*
- **Tysabri accounting**
  - US: BIIB recognizes sales from US shipment of finished product to Elan
  - Ex-US: BIIB recognizes 100% of international sales
  - 50%-50% profit share with partner Elan

* Biogen Idec's TYSABRI revenues in Q3 2006 includes $14 million of revenue that was originally deferred at the time of the initial TYSABRI launch in accordance with the Company's revenue recognition policy. The revenue was recognized in Q3 2006, as the ultimate disposition of the product was determined during the current period.

Executing External Growth Deals

Product / Program	Company
Daclizumab in MS M200 (volociximab) HuZAF (fontolizumab)	PDL BioPharma
BG-12	Fumapharm AG
HSP 90 oral & IV	conforma
Aviptadil	mondoBIOTECH
PML Therapy	Alnylam
CDP323	ucb

biogen idec

biogen idec

James Mullen
Chief Executive Officer

Summary

Q3 2006 Summary

- **Solid financial performance**
  - Strong revenue and earnings growth
  - Increased full year 2006 guidance
- **Successful Tysabri launch since late July with ~2,200 patients dosed**
  - ~4,500 TOUCH start forms, with ~1,700 of those patients infused
  - 500 to 600 patients dosed in Europe
  - ~1,000 practices/infusion centers trained to date
- **Business development momentum sustained in Q3 2006**
  - Three agreements signed in Q3 2006
    - Aviptadil in PAH with mondoBIOTECH
    - RNAi / PML collaboration with Alnylam
    - CDP323 in MS with UCB
- **Pipeline progress**
  - BG-12 in relapsing remitting MS, Galiximab in NHL, Lumiliximab in CLL

biogen idec

Questions & Answers